Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2016

View Archived Issues

FDA clears IND for phase I/II trial of TWB-103 in split-thickness skin graft donor site wounds

TMEPAI shows promise as a therapeutic target in breast cancer

Researchers investigate potential epigenetic mechanism contributing to ADHD

LRBA is novel molecular target with applications in transplant immunology

Fortress Biotech forms subsidiary to develop TBI treatments

Serum miRNAs as novel noninvasive biomarkers for the diagnosis of osteoporosis

MTHFR c.677T is a protective factor of prostate cancer risk in Chinese males

Mabion signs development and commercialization agreement with Mylan for Mabion-CD20

Evotec enters into novel strategic partnership with University of Oxford

European Commission approves Ibrance for HR-positive, HER2-negative metastatic breast cancer

Cell Medica and Baylor to develop off-the-shelf allogeneic cell therapy for cancer

Sosei subsidiaries collaborate to develop novel peptide candidates targeting GPCR for GI disorders

Aganirsen given FDA orphan designation for preventing corneal graft rejection

Sumitomo Dainippon Pharma patents dopamine D4 receptor agonists

CymaBay Therapeutics' MBX-8025 receives FDA orphan drug designation

ViiV Healthcare UK discloses antiviral agents

Takeda Pharmaceutical describes orexin receptor antagonists

Kainos Medicine develops Brd inhibitors

Lead Discovery Center and Qurient present TAM receptor kinases and/or MET inhibitors

Ono Pharmaceutical updates progress of second quarter of fiscal 2016

Matinas' LCNP influenza vaccine protects from infection in preclinical trial

Imugene initiates phase Ib/II study of HER-Vaxx in gastric cancer

FDA grants fast track designation to NS-065 for Duchenne muscular dystrophy

Bristol-Myers Squibb and Infinity Pharmaceuticals sign collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...